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Dr. Lilenbaum: Dr. Wakelee, how much of an impact do
you think the retrospective analysis in elderly patients had in
your use of bevacizumab? Can we get a sense of how
cautious we need to be?
Dr. Wakelee: When I have patients who are in their 70’s and
very fit, I still consider bevacizumab, and have proceeded in
a couple of patients.
Dr. Lynch: I think the analysis was slightly underpowered to
make a firm conclusion and Dr. Wakelee’s interpretation that
we should be cautious is absolutely accurate because, as you
point out, the side effects appear to be higher.
Dr. Socinski: The older we get the more comorbidities we
have, and this is not curative treatment. Bevacizumab is a
good drug, but I think it’s a toxic drug in certain patients, and
so the risk has made me pause for patients over the age of 70.
It does prolong survival but you don’t want to have a
discussion about improving survival and then have a first
cycle grade IV or V event. You have not accomplished the
prolonged survival if you exercise poor judgment with regard
to patient selection.
Dr. Lynch: Is there any mechanistic reason why there should
be a difference between men and women in terms of their
benefit or lack of benefit from bevacizumab?
Dr. Heymach: We don’t have the answer yet. We saw a
gender difference favoring females in ECOG4599 and also in
the two trials of ZD6474 with chemotherapy. One idea is that
angiogenesis is more EGFR-dependent or the tumors are just
more EGFR-dependent in females as compared to males.
VEGF receptor levels are different between the genders.
We’re looking into whether estrogen receptor differences are
driving the differences in angiogenesis.
Dr. Lynch: Dr. Wakelee showed us data that suggested in the
AVAiL trial that both 7.5 mg/kg and 15 mg/kg every three
weeks appeared to be efficacious. Any thoughts about dose of
this drug and what we should be thinking about as we go
forward?
Dr. Jain: I would speculate that if an anti-avascular effect
were the key mechanism for bevacizumab efficacy, that a
higher dose would be better. So to me the AVAiL trial data
suggest that vascular normalization is probably the key mech-
anism. Otherwise one would get better response with a higher
dose of bevacizumab.
Dr. Lynch: The expectation for sunitinib was that continuous
dosing would be better, but the data is certainly suggesting
that’s not the case. Do you interpret this to mean it’s not an
anti-angiogenic mechanism, that it’s more direct anti-tumor
cell effects?
Dr. Heymach: I don’t know how to interpret this data. We all
know from the biomarker data that you can rebound from this
agent relatively quickly. I think we have to be very careful in
drawing conclusions from this, because this is not a random-
ized trial.
Dr. Socinski: But it does raise a lot of discomfort with what
strategy should move forward.
Dr. Lynch: If you give bevacizumab it reduces blood vessel
density about 50-percent after a single dose in rectal carci-
noma patients, but if you look at FDG levels they do not
change. On the other hand, if you give sunitinib, you begin to
see a drop in FDG. Now FDG tells you more about cancer
cells.
Dr. Socinski: Yes. But I’m not aware of any randomized
trials that are being designed to address this issue.
Dr. Lynch: Do we have ways of predicting who is respond-
ing to anti-angiogenic agents? And what are your thoughts on
how one can select patients who may benefit from these
agents, and where are we now?
Dr. Heymach: No, not yet. What you’re talking about is
markers that predict, say, where you’re going to have more
benefit in chemotherapy plus bevacizumab as compared to
just chemotherapy. A lot of the markers now being evaluated
are inflammatory markers. We’re casting a wide net and
looking for predictive markers, because they’re not going to
be obvious. It looks as though having profiles or signatures of
clusters of these cytokines together may be more predictive
than individual markers.
Dr. Lynch: From an imaging standpoint do you think we
have any way of figuring out who benefits from sorafenib or
bevacizumab?
Dr. Sorensen: I think the best we can do is see early respond-
ers, so we can see in a week whether they’re responding. But I
don’t know if we have any way for assessing this at baseline.
Dr. Lynch: How about PET, MRI or CT in helping us select
patients? Are any of these close to allowing us to be able
to select patients who might benefit from anti-angiogenic
therapy?
Dr. Jain: I think we don’t have an answer to that question in
any cancers where anti-angiogenic agents have shown prom-
ise or have been approved. I think we will need an integrated
approach of imaging combined with circulating markers.
Dr. Lynch: Dr. Janne, looking at it from the standpoint of
someone who’s helped to develop markers that are important
in EGFR biology, what are your thoughts on the direction
you’re hearing about in VEGF therapy?
Dr. Janne: I don’t think we have much at the moment in
terms of pretreatment selection, which is where there are
markers for EGFR based therapies. There are obviously some
hints based on the radiographic changes but everyone has to
be treated at that point. So I think there’s a ways to go, and
it’s an active need, because one would assume that these
agents may not work the same in all individuals.
Dr Lynch: I’ve heard some oncologists say that a predictive
biomarker would have to be nearly 100-percent accurate,
because they never want to refuse the opportunity for a
patient to benefit from a drug.
Dr. Hirsch: The percentage of accuracy can be discussed, but
I think that if we want to come close to that, we most likely
need to find a combination of predictive biomarkers. I think
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at the end of the day we need to find a paradigm with
combination.
Dr. Lynch: But the argument is if you have a 20-percent
chance of responding, which cancer patient wouldn’t take
that 20-percent chance?
Dr. Hirsch: I think you are right. But talking about VEGF
inhibitors, we don’t have any biomarker close to those num-
bers you are mentioning. And personally, I think we need to
look into combinations of biomarkers.
Dr. Socinski: The question for these dual inhibitors is
whether there is a difference in the toxicity - do they have the
same risk as bevacizumab?
Dr. Engelman: Just to play devil’s advocate, do you have
any concern that they’re actually not inhibiting angiogenesis
in the patient and that’s why there’s no bleeding?
Dr. Socinski: Of course. Another possibility is that it’s just a
very weak VEGFR inhibitor and maybe that’s why we’re not
getting any bleeding problems in squamous.
Dr. Shepherd: I really wonder whether this is both a weak
VEGF-R and a weak EGFR inhibitor. We have had experi-
ence with it in various tumour types and I do not remember
any patients developing a cavitary lesion, whereas with all the
other VEGF inhibitors, 3- or 6- weeks later, cavitary lesions
are usually seen in responding patients. I question the ratio-
nale of moving this drug forward as opposed to maybe
putting two drugs that are stronger EGFR and stronger VEGF
inhibitors together.
Dr. Lynch: Despite the fact that everybody thinks erlotinib is
a better EGFR inhibitor and that 2171 is a better VEGF
inhibitor, you’ve got to give 6474 credit for passing its
randomized phase 2 test, and actually meeting the endpoints
in these progression free survival trials.
Dr. Shepherd: The maintenance trial in small cell lung
cancer performed by the National Cancer Institute of Canada
Clinical Trials Group was negative.
Dr. Socinski: It may not be inhibiting angiogenesis. It may
have benefits that have nothing to do with inhibiting angio-
genesis.
Dr. Heymach: I believe it’s a moderate VEGF inhibitor. By
IC50s and other criteria, it’s more potent than the first
generation agents like 5416 and probably more than PTK787.
In terms of VEGF inhibition, the two markers that have
modulated significantly were a rise in VEGF and a drop in
cycle VEGF-R2, which is taken as evidence of VEGF path-
way inhibition as monotherapy. When we looked at the
change in soluble VEGF-R2, after 21 days it caused about a
10-percent to 15-percent decrease in soluble VEGF-R2.
Sunitinib, by contrast, after a week, causes about a 40-percent
drop in VEGF-R2 and so does 2171.
Dr. Lynch: Can you comment on some of the difficulties
with squamous cell? Do you think the histology’s going to
matter for the small molecules as well?
Dr. Wakelee: Yes. How much is a difficult question. We
were part of ECOG 2501, which is a randomized discontin-
uation trial with sorafenib that included over 300 patients,
over 20 of whom I treated personally. Two of my patients on
this trial died from hemoptysis and both had squamous cell
histology. They were both patients I wouldn’t have treated
with bevacizumab, but given the data, I felt that it was
reasonable to put them on this study. Autopsies showed that
both had tumor erosion through vessels, which the drug may
have contributed to. We don’t understand why squamous cell
tumors tend to bleed, though the tendency to cavitate may
play a role. We need to better understand exactly what causes
the increased bleeding risk, because some squamous cell
patients are fine with bevacizumab or small molecules, and
some patients with adenocarcinoma aren’t fine with either of
these types of drugs. So although that’s the best marker we
have right now, it’s probably not the true marker of bleeding
risk. We do have to be cautious.
Dr. Lilenbaum: I agree. Now as we move away from a
histology-based classification to a molecular-based classifi-
cation, we’ll be able to understand the different types of
squamous and why some do bleed and others don’t. But with
what we have today I do think squamous histology is impor-
tant.
Dr. Lynch: And would you treat a squamous patient off
protocol with either sunitinib or sorafenib?
Dr. Lilenbaum: Not at this point.
Dr. Lynch: Would you put them on a protocol with sunitinib
or sorafenib?
Dr. Lilenbaum: Yes.
Dr. Hirsch: I think in the future we’ll face the question of
histology much more than we ever have since we started to
distinguish small cell and non-small cell. There are several
studies pointing out that there is a difference in clinical course
and response for adenocarcinoma and nonadenocarcinomas,
so I think there will be much more demand for an exact
histologic classification than we have seen before.
Dr. Socinski: I think that’s definitely true, but on the other
hand I think histology is probably the tip of the iceberg.
Different pathways are probably operative in different de-
grees comparing squamous cell with adenocarcinomas.
Dr. Lynch: As we look at the twelve major trials prior to
4599 combining chemotherapy with other novel targeted
drugs, it appears that most combinations were put together
empirically. And so the question is, how should we be
approaching these combinations more rationally? And partic-
ularly with a drug that we think may be working in antian-
giogenic settings, do cell line based screens help you with
drugs like bevacizumab, sunitinib and sorafenib?
Dr. Engelman: Unfortunately, I think Phase 1 work is really
necessary to fully define toxicity of these combinations.
Beyond Phase 1 is the major question. As soon as we begin
to do all these Phase 1 trials, then are we also committed to
randomized Phase 2 and 3 work, which is ultimately very
expensive? I think that understanding the mechanisms by
which a drug like bevacizumab might interact with chemo-
therapy overall may be important, but how much this can go
beyond Phase 1, I think, is unclear.
Dr. Lynch: What are the best preclinical models? So think-
ing about how you put combinations together, you have
empiricism, which is what has ruled the day so far, you’ve got
cell line based screens where you take cell lines and treat
them with different combinations and look for synergy, and
finally you have murine models- both xenografts and genet-
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ically engineered mice. Now for antiangiogenic drugs my
impression is you’re really limited to one of the two murine
models if you really want to do this prospectively. Is that
true?
Dr. Jain: Yes, you are limited to murine models, but for
anti-angiogenic therapy I think the murine models have
provided very nice insight. Actually all of the work on
normalization was in mice before we saw it in rectal carci-
noma patients. Your choice of animal models is very impor-
tant, and they have to be transgenic or knockouts. I think just
garden variety transplanted tumors are good if you are using
proper doses in the appropriate animal models.
Dr. Hanke: I think the various mouse models have been
useful for testing anti-angiogenic drugs and rational combi-
nation therapies. One of the problems with the murine models
though is that they do not reflect the complexity of human
tumor biology. This is somewhat less of a problem for
anti-angiogenic drugs, as we are targeting host factors. How-
ever, the tumor will influence the stromal environment, so
while positive results in mice is encouraging, they do not
mean the agent will work in a particular human tumor.
Dr. Lynch: Dr. Hanke, from the perspective of someone who
runs a large science endeavor for a pharmaceutical company,
when you’re thinking about putting drugs together and look-
ing for combination or synergistic activity, what do you think,
particularly if angiogenesis is a target, what are your perspec-
tives on how one can best model that preclinically?
Dr. Hanke: We have to devise models to specifically address
a particular hypothesis. So we can’t just go into any standard
xenograft or orthotopic model and expect the results to
translate into man. There are probably 20 or 30 factors
important in the angiogenesis cascade, and there can be a
unique hierarchy to this in different tumors. Once we better
understand the specific drives in a particular tumor, we can
then do a good job to model the biology of that disease for a
specific agent.
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